SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on September 27, 2023, covering events occurring on September 21, 2023. The company, incorporated in Delaware and headquartered in Westport, Connecticut, operates on the NASDAQ Capital Market under the symbol BSGM. The filing details a private placement transaction (September PIPE) and related unregistered equity sales.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report regarding a specific transaction. Key transaction metrics include:
- Total Consideration Raised: $810,200.84
- Common Shares Sold: 1,458,770 shares
- Purchase Price per Share: $0.5554
- Warrants Issued to Investors: 729,385 warrants (50% of shares sold)
- Warrant Exercise Price: $0.4929 per share
- Warrant Terms: Exercisable after 6 months; expire 5.5 years from issuance
- Advisor Compensation: One warrant to purchase 40,511 shares issued to Laidlaw & Company (UK) Ltd. at an exercise price of $0.4929 per share.
Material Changes
The primary material change is the increase in outstanding equity and potential future dilution resulting from the issuance of 1,458,770 shares and 769,896 total warrants (including the advisor warrant). The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
The transaction was conducted under Section 4(a)(2) and Regulation D exemptions from registration. The filing notes that the Purchase Agreement contains standard representations, warranties, and covenants. No specific forward-looking guidance, risk factors, or unusual items beyond the standard terms of the private placement were disclosed in this text.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the current cash balance and burn rate to determine the runway provided by the $810,200.84 raise.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor the 6-month vesting period for the warrants to understand future potential share issuance.
- Check for any subsequent filings regarding the use of proceeds from the September PIPE.